183 related articles for article (PubMed ID: 2012752)
1. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
Estey EH; Kurzrock R; Talpaz M; McCredie KB; O'Brien S; Kantarjian HM; Keating MJ; Deisseroth AB; Gutterman JU
Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752
[TBL] [Abstract][Full Text] [Related]
2. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
Kurzrock R; Talpaz M; Gutterman JU
Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
[TBL] [Abstract][Full Text] [Related]
3. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
Kurzrock R; Talpaz M; Gomez JA; Estey EH; O'Brien S; Hirsch-Ginsberg C; Koller C; Freireich EJ; Gutterman JU
Br J Haematol; 1991 Jul; 78(3):352-8. PubMed ID: 1873220
[TBL] [Abstract][Full Text] [Related]
4. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes.
Verhoef G; Boogaerts M
Br J Haematol; 1991 Oct; 79(2):177-84. PubMed ID: 1958474
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
7. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.
Willemze R; van der Lely N; Zwierzina H; Suciu S; Solbu G; Gerhartz H; Labar B; Visani G; Peetermans ME; Jacobs A
Ann Hematol; 1992 Apr; 64(4):173-80. PubMed ID: 1581405
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts.
Herrmann F; Lindemann A; Klein H; Lübbert M; Schulz G; Mertelsmann R
Leukemia; 1989 May; 3(5):335-8. PubMed ID: 2654495
[TBL] [Abstract][Full Text] [Related]
10. [Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
Berthaud P; Eugène-Jolchine I; Spielmann M; Le Chevalier T; Tursz T
Bull Cancer; 1993 May; 80(5):418-30. PubMed ID: 8173195
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils.
Cairo MS; Christensen R; Sender LS; Ellis R; Rosenthal J; van de Ven C; Worcester C; Agosti JM
Blood; 1995 Oct; 86(7):2509-15. PubMed ID: 7670096
[TBL] [Abstract][Full Text] [Related]
12. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F
Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371
[TBL] [Abstract][Full Text] [Related]
13. Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside.
Economopoulos T; Papageorgiou E; Stathakis N; Asprou N; Karmas P; Dervenoulas J; Bouronikou H; Chalevelakis G; Raptis S
Eur J Haematol; 1992 Sep; 49(3):138-42. PubMed ID: 1446728
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU
Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
17. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
Neidhart JA; Mangalik A; Stidley CA; Tebich SL; Sarmiento LE; Pfile JE; Oette DH; Oldham FB
J Clin Oncol; 1992 Sep; 10(9):1460-9. PubMed ID: 1517789
[TBL] [Abstract][Full Text] [Related]
18. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
[TBL] [Abstract][Full Text] [Related]
20. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes.
Bernell P; Stenke L; Wallvik J; Hippe E; Hast R
Leuk Res; 1996 Aug; 20(8):693-9. PubMed ID: 8913323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
